In abattoir-facing bovine and porcine veterinary practice, perineural infiltration surrounding the cornual nerve during dehorning, the spermatic cord during open castration, and intercostal spaces during thoracic wall suturing is performed with 1.0–2.0% w/v procaine hydrochloride in sterile isotonic diluent. The USP monograph for Procaine Hydrochloride Injection, USP General Chapter <1> Injections, USP <788> Particulate Matter in Injections, USP <790> Visible Particulates, and USP <1207> Container Closure Integrity Testing govern the release parameters; the active pharmaceutical ingredient itself must conform to the USP Procaine Hydrochloride monograph assay window of 98.0–102.0% on the dried basis, with residual solvents controlled under VICH GL18(R2) and elemental impurities under ICH Q3D(R2). The working solution is prepared by dissolving 10.0–20.0 g procaine HCl per 1,000 mL Water for Injection, followed by tonicity adjustment with sodium chloride 0.65–0.75% w/v; where vasoconstriction is required, epinephrine bitartrate is added to a final epinephrine concentration of 1:100,000 (0.001% w/v) and sodium metabisulfite 0.05–0.10% w/v as antioxidant, with pH adjusted to 3.5–5.5 using 0.1 N hydrochloric acid or 0.1 N sodium hydroxide. The solution is sparged with pharmaceutical-grade nitrogen (≥99.999% purity) for 20–30 minutes to reduce dissolved oxygen below 0.5 mg/L before 0.22 µm PVDF membrane filtration; for epinephrine-free formulations, terminal moist-heat sterilization in a saturated steam autoclave at 121°C for 15 minutes is applied, while epinephrine-containing formulations are aseptically filtered and filled in Grade A laminar airflow per EU GMP Annex 1. Terminal presentations include 10 mL, 20 mL, and 50 mL amber Type I borosilicate glass multidose vials sealed with bromobutyl rubber stoppers and aluminum flip-off caps, and 2 mL single-dose glass ampoules. Degradation of procaine HCl in aqueous solution proceeds via ester hydrolysis to 4-aminobenzoic acid and 2-diethylaminoethanol; the reaction follows pseudo-first-order kinetics with minimum hydrolysis rate observed at pH 3.5–4.5, and HPLC analysis per the USP monograph imposes an individual impurity limit of ≤0.5% and total impurities ≤1.0%. Production-scale alkalinity excursions in the diluent preparation vessel above pH 6.0 have been documented to accelerate hydrolysis by approximately 3–4× during 60-minute hold times at 25°C, requiring in-process pH monitoring at 15-minute intervals on 500 L batching stations and rejection of any batch segment exceeding pH 5.8 before filtration.

What Limits Syringeability of 300,000 IU/mL Procaine Benzylpenicillin Suspensions in Cold-Chain Storage?

In the 300,000 IU/mL procaine benzylpenicillin (penicillin G procaine) intramuscular suspension for beef cattle, lactating dairy cows, and swine, the procaine moiety accounts for 41.4% w/w of the procaine benzylpenicillin complex. The USP monograph for Penicillin G Procaine Injectable Suspension, together with 21 CFR Part 522 listing for penicillin G procaine aqueous suspension in animals, defines label potency, sterility per USP <71>, bacterial endotoxins per USP <85>, and particulate count per USP <788>; residual solvent limits follow VICH GL18(R2), and elemental impurity control follows ICH Q3D(R2). A representative 100 mL veterinary presentation contains penicillin G procaine equivalent to 300,000 IU/mL, carboxymethylcellulose sodium 0.40–0.80% w/v as suspending and viscosity modifier, polysorbate 80 ≤0.15% w/v as wetting agent, methylparaben 0.15% w/v and propylparaben 0.02% w/v as preservatives in multidose vials, and Water for Injection q.s.; the suspension is buffered with 0.01–0.02 M sodium citrate to maintain pH 5.5–7.0. The aseptic compounding line for penicillin suspensions employs a double-cone blender charged with gamma-irradiated penicillin G procaine sterile powder (Cobalt-60 dose 25–40 kGy per ISO 11137-1) and sterile vehicle prepared in a separate 200 L jacketed vessel; the powder is wetted under high-shear mixing at 3,000–5,000 rpm for 20–30 minutes using a rotor-stator, followed by colloid milling with a gap setting of 50–100 µm to reduce median particle diameter (D50) to 5–15 µm as verified by laser diffraction per USP <429>. Terminal moist-heat sterilization is not applied because penicillin G procaine undergoes beta-lactam ring hydrolysis under saturated steam conditions; the suspension is filled aseptically into 100 mL and 250 mL Type II glass vials within Grade A/ISO 5 unidirectional airflow per EU GMP Annex 1. The principal process conflict in this suspension class is syringeability through 16G and 18G hypodermic needles at cold-chain temperatures of 5°C. Below 10°C storage, carboxymethylcellulose sodium solutions exhibit pseudoplastic viscosity elevation; a suspension formulated at 0.80% w/v CMC-Na can exceed 400 cP at 5°C versus 120–180 cP at 20°C when measured on a Brookfield RV viscometer at 50 rpm with Spindle LV-3. Injection force through an 18G × 1.5 inch needle at a crosshead speed of 50 mm/min has been recorded in the range of 12–25 N at 20°C; the same formulation at 5°C requires 40–60 N, exceeding the ergonomic threshold for single-hand injection. Release viscosity specification is therefore set at 80–200 cP at 25°C and shear rate 10 s−1, and cold-chain storage instructions prohibit freezing and require warming to 18–25°C for 30 minutes before administration.

Formulation variable (CMC-Na w/v)	D50 (µm)	Viscosity at 25°C (cP)	Injection force at 20°C (N)	Injection force at 5°C (N)
0.40%	5–8	60–90	10–14	25–35
0.60%	6–10	100–150	12–18	35–50
0.80%	7–12	160–220	18–25	45–60

The terminal presentations include 100 mL and 250 mL multidose vials for cattle and swine, 30 mL vials for sheep and veal calves, and 10 mL single-dose vials for companion animal use; all are sealed with butyl rubber stoppers and aluminum overseals. Batch-to-batch variance in colloid mill gap drift beyond ±20 µm during 8-hour filling campaigns has been linked to a 2–4 µm upward shift in D90, which raises sedimentation velocity and shortens redispersibility time from 20 seconds to 5 seconds on manual shaking; in-line laser diffraction probes positioned after the mill are calibrated every 4 hours against a 3 µm reference standard to maintain D50 within the certified range.Where objective lameness localization in performance horses requires distal limb perineural anesthesia, 2.0% w/v procaine hydrochloride solution (20 mg/mL) without vasoconstrictor is injected adjacent to the palmar digital nerve at the level of the proximal sesamoid bones in volumes of 1.0–2.0 mL per site. The solution must meet the sterility and particulate requirements of USP <71> Sterility Tests and USP <788> Particulate Matter in Injections; because these diagnostic injections are frequently extralabel with respect to species-specific approval, the prescribing veterinarian operates under AMDUCA 21 CFR 530 and the American Association of Equine Practitioners statements on diagnostic anesthesia, while residual solvent and elemental impurity control follows VICH GL18(R2) and ICH Q3D(R2). The 2.0% w/v formulation is prepared with 20.0 g procaine HCl per 1,000 mL Water for Injection; the solution is made isotonic with 0.65% w/v sodium chloride and adjusted to pH 4.0–5.0 to minimize ester hydrolysis. No epinephrine is added, because alpha-adrenergic vasoconstriction alters lameness response interpretation via digital vasospasm and reversible false-positive nerve block. The finished solution is sterilized by terminal autoclaving at 121°C for 15 minutes after filling into 10 mL amber Type I glass single-use vials under nitrogen overlay; stability studies at 25°C/60% RH demonstrate procaine HCl content remains within 95.0–105.0% of label for 24 months when stored protected from light, as quantified by stability-indicating HPLC with UV detection at 290 nm. Terminal presentations are 10 mL single-dose vials and 5 mL single-dose ampoules; rubber stoppers are halobutyl to minimize leachables and procaine HCl sorption below the analytical threshold. Batch-to-batch variability in pH adjustment across 500 L batching vessels has been documented to require in-line process analytical technology control; near-infrared spectroscopy monitoring of procaine HCl concentration at ±2.0% relative standard deviation has reduced rework rates from 4% to 0.5% on three consecutive production campaigns.

When 2% Procaine HCl Cartridges Require Autoclavable Cyclic Olefin Polymer Barrel Materials

Across companion animal dental units performing full-mouth extractions in cats and periodontal flap surgery in dogs, 1.7 mL and 1.8 mL single-use anesthetic cartridges contain 2.0% w/v procaine hydrochloride with epinephrine bitartrate equivalent to 1:100,000 epinephrine (0.01 mg/mL). The cartridge assembly is governed by ISO 11499:2014 for dimensional tolerances on flange diameter (7.05 ± 0.05 mm) and plunger travel force (≤15 N); elastomeric closures conform to ISO 8362-2, and leachable and cytotoxicity profiles follow ISO 10993-5 and ISO 10993-12. The anesthetic solution contains 20.0 g procaine HCl per 1,000 mL Water for Injection, sodium chloride 0.65% w/v, edetate disodium 0.05 mg/mL as chelating agent, sodium metabisulfite 0.05–0.10% w/v as antioxidant, epinephrine bitartrate to provide 1:100,000 epinephrine, and hydrochloric acid/sodium hydroxide for pH adjustment to 3.5–4.5. The glass or cyclic olefin polymer cartridge barrels are washed, siliconized by spray application of a 0.1–0.3 µm polydimethylsiloxane layer, and loaded with chlorobutyl rubber plungers; the solution is degassed under vacuum (−0.8 bar) and passed through a 0.22 µm double-layer PVDF filter before aseptic filling in a Grade A tunnel at line speeds of 200–400 cartridges per minute. Cartridges without epinephrine may be terminally sterilized at 121°C for 15 minutes, whereas epinephrine-containing cartridges are aseptically filled and maintained at 2–8°C until crimping. The process conflict arises from the heat sensitivity of epinephrine bitartrate, which undergoes oxidative racemization above 30°C and at pH 5.0, and the glass barrel delamination risk observed on Type I borosilicate cartridges exposed to pH 3.5–4.5 solutions over 24-month storage. Cyclic olefin polymer barrels exhibit lower extractable profiles under acidic conditions but require mold temperature control between 120°C and 140°C to prevent birefringence-induced dimensional distortion; dimensional validation follows ISO 11499:2014 Annex A for flange breakage force. Field data from cartridge filling lines indicate that plunger insertion force above 20 N causes 3–5% rejection rates due to misaligned plunger ribs, necessitating in-line force monitoring with a tolerance of ±2 N. Terminal presentations are 1.7 mL and 1.8 mL glass or cyclic olefin polymer cartridges packed 50 per canister or 10 per blister tray, and 2.2 mL cartridges for equine dental impression and extraction procedures where momentary regional anesthesia of the maxillary nerve is required.

Lyophilized Procaine HCl Granules and In-Syringe Reconstitution Metrics

Because mobile equine practitioners and remote cattle stations require non-refrigerated stable presentations, terminal lyophilized procaine hydrochloride granules for field reconstitution are supplied to veterinary distribution centers. The granules are produced from a sterile aqueous bulk solution containing 10.0% w/v procaine HCl and 3.0% w/v mannitol as matrix former; the solution is filtered through 0.22 µm PVDF and filled into 5 mL or 10 mL Type I glass vials at fill volumes of 2 mL or 4 mL before loading onto stainless steel lyophilizer shelves. The lyophilized presentation is controlled under the USP Procaine Hydrochloride monograph, USP <921> Water Determination by Karl Fischer titration for residual moisture ≤1.0% w/w, USP <71> Sterility Tests, and USP <1207> Container Closure Integrity Testing; the lyophilization cycle is validated per EU GMP Annex 1 for sterile lyophilized products. Each 2 mL fill contains 200 mg procaine HCl and 60 mg mannitol; reconstitution with 8.6 mL Water for Injection produces 10 mL of 2.0% w/v solution, which is the standard working concentration for infiltration and regional nerve block in large animals. The lyophilization cycle uses a freezing ramp from 5°C to −45°C at 0.5°C/min, primary drying at −15°C shelf temperature and 0.1 mbar chamber pressure for 18–24 h, and secondary drying at 25°C for 6–8 h until thermocouple readings stabilize within ±1°C; the resulting cake has a density of 0.25–0.35 g/cm³ and visual reconstitution time ≤60 seconds. Residual moisture content above 1.2% w/w has been observed in production-scale lyophilizers with shelf temperature heterogeneity exceeding ±3°C across 2 m² shelf areas; this moisture excess accelerates hydrolytic degradation of procaine HCl to 4-aminobenzoic acid during 24-month storage at 25°C, reducing potency by 1.5–2.5% per year versus 0.3–0.5% per year at ≤0.8% w/w residual moisture. Karl Fischer analyses on composite samples from shelf edges reveal a 0.3–0.6% w/w within-batch moisture gradient, which is mitigated by a 12-hour equilibration step at 22°C and 35% RH before capping. Terminal presentations include 5 mL and 10 mL vials each paired with 10 mL or 20 mL diluent ampoules in peelable blister trays, and 50-vial hospital packs for veterinary teaching hospitals; the diluent ampoules are terminally sterilized at 121°C for 15 minutes and tested for sterility per USP <71> from each autoclave load.

Sterile Veterinary Pharmacy Compounding from Bulk Procaine Hydrochloride Under USP 795 and 797

Within USP-regulated veterinary compounding pharmacies, bulk procaine hydrochloride API in 25 kg fiber drums with double polyethylene liners is used to prepare patient-specific sterile injectable solutions and oral mucosal gels for companion animals. The compounding operation is governed by USP <797> Pharmaceutical Compounding—Sterile Preparations for injectable products and USP <795> for nonsterile preparations when oral mucosal gels are produced; the end product falls under FDA 21 CFR 530 extralabel use provisions when no approved veterinary drug is available for the diagnosed condition. A 1.0% w/v procaine HCl injection is compounded by dissolving 1.0 g procaine HCl in sufficient 0.9% sodium chloride injection to make 100 mL; the solution is passed through a 0.22 µm sterile PVDF syringe filter in an ISO 14644-1 Class 5 laminar airflow workstation, with filter integrity confirmed by bubble point test before and after filtration. The compounded preparation is assigned a beyond-use date of 14 days at 2–8°C as a low-risk sterile preparation per USP <797>, and terminal sterilization is not employed in the pharmacy setting. Production scales in compounding pharmacies typically range from 5 mL to 100 mL per batch, with a final visual inspection against black and white backgrounds under 100–150 lux illumination to meet USP <790> visible particulate requirements. Terminal product types include patient-specific disposable syringes, 30 mL and 50 mL multidose vials, and 100 mL injectable bags for surgical suite restocking.

Compounded preparation parameter	Standard / Code	Specification
Sterility	USP <71>	No growth after 14 days
Particulate matter	USP <788>	≥10 µm: NMT 6,000/container; ≥25 µm: NMT 600/container
Bacterial endotoxins	USP <85>	≤2.0 EU/mg procaine HCl
Cleanroom classification	ISO 14644-1 Class 5	≥0.5 µm particles ≤3,520/m³
Filter integrity	ASTM F838-20	0.22 µm PVDF bubble point ≥3.2 bar
Container closure integrity	USP <1207>	Dye ingress vacuum decay, no breach

The compounding workflow requires segregated storage of procaine HCl API in a temperature-mapped room at 15–25°C and ≤40% RH, with desiccant canisters monitored by data loggers calibrated every 12 months; opened drums are sampled for assay and water content by Karl Fischer titration per USP <921> before each compounding session. Documented failure modes in pharmacy practice include incidental introduction of particulate matter from coring of 25 kg drum liners and pH drift in compounded solutions stored beyond 7 days at room temperature; both failure modes are mitigated by single-use subsampling scoops and refrigerated quarantine of prepared syringes at 2–8°C until administration.